Cannabinoid Drug Developer, Cannabics Pharmaceuticals, Files Colon Cancer Treatment Patent

A Cannabics Pharmaceuticals statement from Wednesday says the company filed a US provisional patent for a colon cancer treatment it has created and that’s based on a study called “Composition and Method for Treating Colon Cancer with Cannabinoids.” The formula for the patent is a very powerful cannabis concoction containing cannabinoids that are non-psychoactive and will not cause a feeling of being high for the user. Cannabics Pharmaceuticals says the cannabinoids have anti-tumor effects for treatment of colon cancer and can be used independently or as a complement.

The New Formula Discovered while Studying Gastrointestinal Cancers

The company was testing the effects of cannabis over gastrointestinal cancers when the unique formula was first found. Last month, Cannabics Pharmaceuticals said it has completed a study where cannabigerolic acid (CBGA) and cannabidivarin (CBDV) were used against colon cancer with high doses. The conclusion to the study’s test was that both these cannabinoids have anti-tumor properties, but only in some cancers, not in all of them.

Cannabis Is Gaining More and More Terrain in the Fight Against Cancer

Until now, there hasn’t been a treatment for cancer. Cannabis seems to be used more and more as a complement in cancer treatments, not to mention it became legalized in all 50 US states and Canada. All this has helped with reducing the stigma around marijuana. With more research money being invested in testing on all the ways the plant could be used in the search for cures against many diseases, different cancers included.

Cannabics Pharmaceuticals is an American company located and  licensed with the Israeli Ministry of Health in Israel, at Tel Aviv. to conduct scientific research on how cannabinoids can work to kill cancer. According to the Cannabics Pharmaceuticals official website, the company’s future goal is “By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy.”

Charnell Lock

Charnell Lock lives in sunny San Diego but is originally from North Carolina and has been writing professionally since 2011. After four years with the Navy and an Associate's Degree in Liberal Arts, Charnell found her passion in creating diverse content with well-formatted research. Along with her years in active duty service, she is capable of crafting whimsical short stories to medical-oriented papers as her capacity to contribute here is immense and will be a staple for many years to come.

Share

Recent Posts

  • Guides

SEO Super Tool — Probe a2ad5884

Тестовая проверка публикации постов SEO Super Tool (временный пост, будет удалён).

1 day ago
  • public

Software reliability check MAGICQA20261122HB 00002

MAGICQA20261122HB is a temporary publication test label for a neutral technical review of finance software…

1 month ago
  • public

Software reliability check MAGICQA20261121EB 00147

MAGICQA20261121EB is a temporary publication test label for this neutral technical guide to finance software…

1 month ago
  • public

Software reliability check MAGICQA20261122SA 01007

Software quality assurance relies on deliberate checks that show whether an application behaves consistently under…

1 month ago
  • public

Software reliability check MAGICQA20261122MA 01143

Finance software handles balances, payments, statements, forecasts, and other sensitive records, so reliability checks must…

1 month ago
  • Gummies

Condor CBD Gummies – Shocking Customer Scam Concerns?

The Condor CBD Gummies have been the talk of the hemp-derived cannabidiol edibles as of…

4 years ago